Key Drivers
- Large cash buffer
- Zero revenue/losses
- Rising long‑term debt
AIAI Summary
Celcuity has shifted from a long‑horizon R&D story into a near‑term, high‑conviction regulatory/commercial binary where PDUFA (wild‑type gedatolisib) and early payer/access outcomes will largely determine whether its credible Phase 3 data convert into real revenue upside or force dilutive financing. Monitor PDUFA outcome, Q4/2025 cash/liabilities and term‑loan draw conditions, plus manufacturing and early reimbursement metrics — a positive PDUFA plus rapid payer wins could unlock substantial upside, while a miss or covenant/scale‑up issues would materially compress valuation.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Large cash buffer
- •Zero revenue/losses
- •Rising long‑term debt
Celcuity has a very strong liquidity buffer (cash + short‑term investments ≈ $455M, current ratio 12.26) but zero revenue, heavy quarterly losses and rising long‑term debt that materially increase cash‑burn and leverage risk.
Price Behavior
Key Price Behavior Insights:
- •Near-term pullback
- •Below last month SMA
- •Support near $104–$105
The stock is undergoing a clear near‑term pullback, trading below its last month SMA (~$111.23) after falling from ~$117.10 to $106.04 and resting above support in the $104–$105 area while needing a break above $111 then $115–$117 to shift bullish.
Drop from ~$117.10 on 2026-03-10 to $106.04 on 2026-03-20 signaling a sharp last-month pullback
Sentiment & News
Key News Insights:
- •Phase 3 data
- •NDA/PDUFA timeline
- •Institutional buying
Celcuity's recent positive Phase 3 data, upcoming gedatolisib NDA/PDUFA timeline, and active institutional buying have driven strong stock momentum and favorable analyst coverage.
The convergence of clinical progress, regulatory catalysts, and rising institutional ownership should support upside momentum into the PDUFA window while keeping volatility elevated
Similar Companies in Healthcare
Other companies in the same sector with AI ratings